➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
McKinsey
Medtronic
Dow
Mallinckrodt

Last Updated: May 31, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PARSABIV

» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for PARSABIV

Trial ID Title Status Sponsor Phase Start Date Summary
NCT03795558 A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients Not yet recruiting Amgen Phase 2 2019-02-01 This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.
NCT03795558 A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients Not yet recruiting Prim. Priv. Doz. Dr. Daniel Cejka Phase 2 2019-02-01 This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal disease patients on chronic hemodialysis with secondary hyperparathyroidism.
NCT03960437 The Effect of Etelcalcetide on CKD-MBD Recruiting Thomas Nickolas, MD MS Phase 2 2018-09-06 The proposed study will investigate the effects of etelcalcetide on the bone and blood-vessel health in patients with CKD-MBD. The investigators will test if etelcalcetide makes bone and blood-vessels healthier. The study hypotheses are that are that etelcalcetide keeps bones strong and lowers the risk of calcium deposits in blood vessels. In Aim 1, the investigators will test if 9-months of treatment with etelcalcetide improves bone strength in twenty ESKD patients with hyperparathyroidism (HPT) by bone biopsy. In Aim 2, the investigators will test if 9-months of treatment with etelcalcetide decreases serum propensity to calcify blood vessels. The potential significance of this study is to provide first-time data on the ability of etelcalcetide to protect bone and blood-vessel health in patients with ESKD.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for PARSABIV

Condition Name

Condition Name for PARSABIV
Intervention Trials
End Stage Renal Disease 1
Chronic Kidney Disease Mineral and Bone Disorder 1
Vascular Calcification 1
Renal Osteodystrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for PARSABIV
Intervention Trials
Calcinosis 2
Vascular Calcification 1
Kidney Failure, Chronic 1
Renal Insufficiency, Chronic 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for PARSABIV

Trials by Country

Trials by Country for PARSABIV
Location Trials
Austria 1
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for PARSABIV
Location Trials
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for PARSABIV

Clinical Trial Phase

Clinical Trial Phase for PARSABIV
Clinical Trial Phase Trials
Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for PARSABIV
Clinical Trial Phase Trials
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for PARSABIV

Sponsor Name

Sponsor Name for PARSABIV
Sponsor Trials
Prim. Priv. Doz. Dr. Daniel Cejka 1
Amgen 1
Thomas Nickolas, MD MS 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for PARSABIV
Sponsor Trials
Other 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Harvard Business School
McKinsey
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.